Differential Effect of Previous Antiplatelet Use on Stroke Severity According to Stroke Mechanism
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Wook-Joo | - |
dc.contributor.author | Ko, Youngchai | - |
dc.contributor.author | Yang, Mi Hwa | - |
dc.contributor.author | Im, Sun-Hye | - |
dc.contributor.author | Park, Jung Hyun | - |
dc.contributor.author | Lee, JiSung | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Han, Moon-Ku | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.date.accessioned | 2021-09-08T02:55:34Z | - |
dc.date.available | 2021-09-08T02:55:34Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 0039-2499 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116395 | - |
dc.description.abstract | Background and Purpose-The effect of previous antiplatelet use on stroke severity is controversial. We assume that this controversy is attributable to its difference according to the stroke mechanism. Methods-Using a prospective stroke registry, patients who were hospitalized because of ischemic stroke and had relevant lesions on MRI were selected. Patients who were using anticoagulants or whose stroke subtype was categorized as stroke of other determined etiology or undetermined etiology were excluded. Baseline stroke severity was measured using the National Institutes of Health Stroke Scale scores at presentation and was compared between no previous antiplatelet users and previous antiplatelet users with stratification by stroke subtypes. Results-Among the 1622 patients, a total of 490 (30.2%) patients reported use of an antiplatelet within 1 week of stroke onset. The baseline National Institutes of Health Stroke Scale score showed no difference between the nonantiplatelet and antiplatelet groups by crude comparison. However, the interaction between previous antiplatelet use and stroke subtype was significant (P = 0.023) in a multivariable analysis; when the study subjects were stratified by stroke subtype, the difference in baseline National Institutes of Health Stroke Scale between the nonantiplatelet and platelet groups was significant in the large artery atherothrombosis group but not in those with cardioembolism and small-vessel occlusion before and after adjustments. Conclusions-Our study suggests that the reduction of initial stroke severity in the previous antiplatelet users may differ by stroke mechanism. (Stroke. 2010; 41: 1200-1204.) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | ACUTE ISCHEMIC-STROKE | - |
dc.subject | FACTOR SURVEILLANCE SYSTEM | - |
dc.subject | ANTITHROMBOTIC AGENTS | - |
dc.subject | ATRIAL-FIBRILLATION | - |
dc.subject | ASPIRIN USE | - |
dc.subject | TRIAL | - |
dc.subject | OUTCOMES | - |
dc.subject | THERAPY | - |
dc.subject | DISEASE | - |
dc.subject | BENEFIT | - |
dc.title | Differential Effect of Previous Antiplatelet Use on Stroke Severity According to Stroke Mechanism | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1161/STROKEAHA.110.580225 | - |
dc.identifier.scopusid | 2-s2.0-77953233046 | - |
dc.identifier.wosid | 000278019400023 | - |
dc.identifier.bibliographicCitation | STROKE, v.41, no.6, pp.1200 - 1204 | - |
dc.relation.isPartOf | STROKE | - |
dc.citation.title | STROKE | - |
dc.citation.volume | 41 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1200 | - |
dc.citation.endPage | 1204 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | ACUTE ISCHEMIC-STROKE | - |
dc.subject.keywordPlus | FACTOR SURVEILLANCE SYSTEM | - |
dc.subject.keywordPlus | ANTITHROMBOTIC AGENTS | - |
dc.subject.keywordPlus | ATRIAL-FIBRILLATION | - |
dc.subject.keywordPlus | ASPIRIN USE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | BENEFIT | - |
dc.subject.keywordAuthor | antiplatelet drugs | - |
dc.subject.keywordAuthor | cerebral infarction | - |
dc.subject.keywordAuthor | stroke classification | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.